Infection Control Market to Reach USD 139.94 Billion by 2030, Driven by Hospital-Acquired Infection Prevention and Sterilization Demand
"Infection Control Market"
Mordor Intelligence has published a new report on the Infection Control Market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
According to a 2025 report on infection control market by Mordor Intelligence, the market is estimated at USD 102.36 billion in 2025 and is projected to reach USD 139.94 billion by 2030, growing at a CAGR of 6.45% during the forecast period
The infection control market plays a crucial role in maintaining hygiene and safety standards across hospitals, laboratories, pharmaceutical production units, and life sciences facilities. Infection prevention solutions such as sterilization, disinfection, and cleaning consumables are critical to minimize risks to patients, healthcare staff, and consumers. The market growth is attributed to rising hospital-acquired infection cases, stringent guidelines to control contamination, and high demand for effective sterilization products in medical device reprocessing.
Key Trends
Hospital-acquired infections driving product demand
The report highlights that the increasing number of hospital-acquired infections (HAIs) has made infection control a critical operational area in hospitals and clinics. These infections prolong hospital stays and increase treatment costs, making preventive sterilization, disinfectant usage, and effective waste disposal mandatory to maintain public health standards.
Sterilization segment maintains dominance
Sterilization remains the largest segment in the infection control market, supported by the widespread use of sterilizers in hospitals, outpatient facilities, and diagnostic labs for surgical instrument reprocessing and equipment sterilization. Within sterilization, the use of low-temperature sterilizers is increasing to protect heat-sensitive instruments.
Disinfectants witnessing rising application
Disinfectants are used extensively for surface cleaning, floor cleaning, and equipment cleaning in critical care units and operating theatres. The trend of ready-to-use disinfectant wipes, sprays, and solutions is growing due to convenience and time efficiency in hospitals and diagnostic centres.
Pharmaceutical and life sciences sector driving demand
Beyond hospitals, pharmaceutical manufacturing units, research laboratories, and biotechnology firms require advanced contamination control. The demand for cleanrooms and sterile processing areas contributes significantly to market expansion in the infection control segment.
North America remains the largest market
According to the Mordor Intelligence report, North America continues to hold the largest market share driven by the high number of surgeries performed annually, better healthcare infrastructure, and stringent infection control regulations by organizations such as the CDC and FDA.
Market Segmentation
The infection control market report segments the industry into Product, Service Delivery Mode, End User and Geography.
By Product
Sterilization Products and Services: Includes equipment such as autoclaves and low-temperature sterilizers, along with contract sterilization services. These solutions ensure medical devices and surgical instruments are free from viable microorganisms before reuse.
Cleaning and Disinfection Products: Encompasses disinfectant liquids, sprays, wipes, and detergents used for cleaning surfaces, instruments, and hospital environments to reduce contamination risks.
Protective Barriers: Includes gloves, gowns, face masks, and drapes used by healthcare professionals to prevent cross-contamination during surgical or diagnostic procedures.
By Service Delivery Mode
In-house Infection Control: Refers to infection prevention and control activities managed within healthcare facilities, pharmaceutical manufacturing units, and laboratories using their own sterilization equipment, disinfectants, and staff. Hospitals and large medical centres often maintain in-house sterilization departments to handle equipment reprocessing and facility hygiene efficiently without outsourcing.
Contract Infection Control: Outsourcing sterilization and contamination control services to third-party providers. This is widely used by medical device manufacturers and pharmaceutical companies that require large-scale sterilization but prefer specialized contract service providers to ensure regulatory compliance, cost efficiency, and access to advanced sterilization technologies without heavy capital investments.
Hospitals and Clinics: The largest segment, driven by the constant need for sterilization and disinfection in surgical theatres, ICUs, OPDs, and diagnostic labs to prevent healthcare-associated infections.
Medical Device Companies: Use sterilization services and equipment for manufacturing sterile medical products and packaging to comply with international quality and safety standards.
Pharmaceutical and Life Sciences Companies: Require stringent contamination control and sterilization solutions in production lines, cleanrooms, and research facilities to ensure product safety and regulatory compliance.
Pharmaceutical and Biologics Manufacturers: These include companies involved in producing pharmaceutical drugs, vaccines, and biologic products. They require stringent sterilization, contamination control, and cleanroom hygiene practices throughout manufacturing to ensure product safety, efficacy, and compliance with global regulatory standards.
Life-Science and Food-Processing Facilities: Facilities engaged in life sciences research, diagnostics, and food processing depend on infection control measures to maintain sterile environments, prevent cross-contamination, and uphold product quality and safety during processing, packaging, and storage operations.
Ambulatory Surgery Centers: These are outpatient surgical facilities that perform procedures not requiring hospital admission. Infection control practices such as equipment sterilization, use of disinfectants, and protective barriers are critical to ensure patient safety and prevent surgical site infections in these high-throughput environments.
By Geography
North America: Largest market with well-established infection control guidelines.
Europe: Growing due to increased healthcare spending and focus on patient safety.
Asia-Pacific: Expected to witness the fastest growth owing to rising surgical procedures, healthcare infrastructure development, and increasing awareness.
Middle East & Africa: Growth driven by improving healthcare systems and infection prevention investments.
South America: Developing market with gradual adoption of stringent infection control standards.
Key Players
The infection control market report identifies key companies providing sterilization, disinfection, and protective barrier solutions.
Fortive (Advanced Sterilization Products): Advanced Sterilization Products (ASP) is a part of Fortive Corporation. ASP is known for providing infection prevention solutions, particularly focusing on sterilization and disinfection products used in hospitals and healthcare facilities.
3M Company: Offers a wide range of infection prevention products including sterilization assurance, hand hygiene, and barrier solutions catering to hospitals globally.
Steris Corporation: Known for its sterilization equipment, instrument reprocessing products, and infection prevention consumables for healthcare and life sciences sectors.
Getinge AB: Provides sterilizers, washer-disinfectors, and associated consumables with a strong market presence in hospital sterile processing departments.
Cantel Medical Corp: Specializes in endoscope reprocessing systems, high-level disinfectants, and infection control consumables supporting GI and surgical care.
These companies focus on expanding their infection prevention product portfolios through strategic acquisitions, product launches, and partnerships with hospitals, labs, and pharmaceutical companies to address growing infection control needs.
Conclusion
The infection control market is set for robust growth, with a projected value of USD 139.94 billion by 2030. Rising cases of hospital-acquired infections, expanding surgical procedures, and increasing contamination control requirements in pharmaceuticals and life sciences will continue to support market expansion. While North America remains dominant, Asia-Pacific is expected to witness the fastest growth in the coming years due to healthcare infrastructure development and heightened awareness regarding infection control practices. Companies investing in product innovation and strategic collaborations are well-positioned to meet evolving hospital, laboratory, and industrial hygiene demands.
Industry Related Reports
Dental Infection Control Market: The dental infection control market is segmented by Product Type (Equipment and Consumables), End User (Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report provides the value (in USD million) for these segments.
Surgical Site Infection Control Market : Surgical Site Infection Control Market: is segmented by Product (Manual Preprocessors Solution, Disinfectants, and more), Surgery/Procedure (Cataract Surgery, Cesarean Section, and more), Type of Infection (Superficial Incisional SSI, and more), End User (Hospitals, and more), and Geography (North America, Europe, and more). The report provides the value (in USD million) for these segments.
Get More Insights:
Infection surveillance solutions market : Infection Surveillance Solutions Market is segmented by Type (Surgical-Site Infections, Blood-Stream Infections, Catheter-Associated UTIs, and Ventilator-Associated Pneumonia), Offering (Software and Services), Deployment Model (On-Premises and Cloud), End User (Hospitals, Long-Term Care Facilities, Ambulatory Surgery Centers, and more), and Geography. The report provides the market forecasts in terms of value (USD).
About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
For any inquiries or to access the full report, please contact: media@mordorintelligence.com https://www.mordorintelligence.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Trump sends Powell a list of global interest rates, says Fed should lower rate to 1%
President Donald Trump on Monday continued hammering at the U.S. Federal Reserve to ease monetary policy, sending Fed Chair Jerome Powell a list of central bank interest rates around the world adorned with handwritten commentary saying the U.S. rate should be between Japan's 0.5 per cent and Denmark's 1.75 per cent, and telling him he was 'as usual, 'too late.'' 'You should lower the rate by a lot. Hundreds of billions being lost,' Trump said in the note, which was also posted to social media with further commentary from the President saying that being a central banker in the U.S. was 'one of the easiest, yet most prestigious jobs in America, and they have should be paying 1% interest, or better!' A 1 per cent policy rate in the past in the U.S. has been associated with weak, even recessionary economic growth rates and periods of low inflation. As have many of Trump's posts on monetary policy, this one seemed to conflate the benchmark short-term interest rate set by the Fed with the interest rate investors demand to hold U.S. and other debt, which can be influenced by Fed policy but is also connected to views about the U.S. economy, inflation, geopolitics and institutional stability. With the unemployment rate low and inflation above their 2 per cent target, Fed officials have been reluctant to cut interest rates from the current 4.25 per cent to 4.5 per cent range until it is clear that the Trump administration's tariff plans won't lead to a fresh surge in prices. Federal Reserve officials continued to raise those concerns on Monday, while Treasury Secretary Scott Bessent began mapping out the likely plan for naming Powell's replacement for when he leaves the job next May. Trump cannot fire Powell over a policy dispute, but last week urged him to resign. Tariff threats put the Federal Reserve in 'uncomfortable purgatory' Bessent in recent days, by contrast, has pointed to a more conventional handover of power at the Fed instead of attempts to influence monetary policy through early appointment of a 'shadow chair' or other methods. 'There's a seat opening up ... in January. So we've given thought to the idea that perhaps that person would go on to become the chair when Jay Powell leaves in May,' Bessent said on Bloomberg TV. Current Governor Adriana Kugler's term expires in January. Bessent on Friday said a January opening would 'probably mean an October, November nomination' with Senate confirmation following. One person under consideration as chair, Governor Christopher Waller, is already on the board and participating in monetary policy discussions; others, like former governor Kevin Warsh, would remain on the sidelines until a seat comes open and the nominee for it is confirmed by the Senate. Though Trump's insistence on rate cuts could make for a difficult confirmation hearing – the Fed is supposed to act independently of the wants of elected officials – data this summer will be key to whether tensions between the White House and the central bank intensify or ease in coming weeks if policy makers find a path to rate cuts on their own. Investors expect the Fed to resume cutting the benchmark policy rate at the September meeting and move steadily lower from there. Economists from Goldman Sachs, who have been pessimistic about the U.S. growth and inflation outlook and had expected the Fed to wait until the end of the year to cut rates, on Monday pulled their estimated first cut into September as well. 'We thought that the peak summer tariff effects on monthly inflation would make it awkward to cut sooner. But the very early evidence suggests that the tariff effects look a bit smaller than we expected, other disinflationary forces have been stronger, and we suspect that the Fed leadership shares our view that tariffs will only have a one-time price level effect,' Goldman economists wrote. Waller has said cuts could be warranted as soon as the Fed's July meeting, and paused if inflation does begin to rise. The Fed receives new jobs data on Thursday, covering the month of June, which will indicate if the labour market is beginning to sputter, a development that could also add to the case for rate cuts sooner rather than later. New inflation data is released next week. July 9 is also top of mind for the Fed: That's the day the current suspension of some of Trump's tariffs expires, and it remains unclear whether import taxes will skyrocket or Trump's program be delayed again pending negotiations. Federal Reserve Bank of Atlanta President Raphael Bostic repeated on Monday that he still sees the central bank cutting its interest rate target just once this year, while suggesting there's no urgency to act given the level of uncertainty. 'I think we actually have some luxury to be patient because labour markets are actually quite solid,' Bostic said in an event hosted by Market News International. 'I think there is actually more pricing to come, and it is more a question of time, of when and not if ... This is still going to take some time before we'll sort of know the answer to those sorts of things.'
CTV News
2 hours ago
- CTV News
Over 14 million people could die from U.S. foreign aid cuts: study
Demonstrators and lawmakers rally against U.S. President Donald Trump and his ally Elon Musk as they disrupt the federal government, including dismantling the U.S. Agency for International Development, which administers foreign aid approved by Congress, on Capitol Hill in Washington, Wednesday, Feb. 5, 2025. (AP Photo/J. Scott Applewhite) PARIS, France — More than 14 million of the world's most vulnerable people, a third of them small children, could die because of the Trump administration's dismantling of U.S. foreign aid, research projected on Tuesday. The study in the prestigious Lancet journal was published as world and business leaders gather for a UN conference in Spain this week hoping to bolster the reeling aid sector. The U.S. Agency for International Development (USAID) had provided over 40 percent of global humanitarian funding until Donald Trump returned to the White House in January. Two weeks later, Trump's then-close advisor -- and world's richest man -- Elon Musk boasted of having put the agency 'through the woodchipper'. The funding cuts 'risk abruptly halting -- and even reversing -- two decades of progress in health among vulnerable populations,' warned study co-author Davide Rasella, a researcher at the Barcelona Institute for Global Health (ISGlobal). 'For many low- and middle-income countries, the resulting shock would be comparable in scale to a global pandemic or a major armed conflict,' he said in a statement. Looking back over data from 133 nations, the international team of researchers estimated that USAID funding had prevented 91 million deaths in developing countries between 2001 and 2021. They also used modelling to project how funding being slashed by 83 percent -- the figure announced by the U.S. government earlier this year -- could affect death rates. The cuts could lead to more than 14 million avoidable deaths by 2030, the projections found. That number included over 4.5 million children under the age of five -- or around 700,000 child deaths a year. For comparison, around 10 million soldiers are estimated to have been killed during World War I. Programmes supported by USAID were linked to a 15-percent decrease in deaths from all causes, the researchers found. For children under five, the drop in deaths was twice as steep at 32 percent. USAID funding was found to be particularly effective at staving off preventable deaths from disease. There were 65 percent fewer deaths from HIV/AIDS in countries receiving a high level of support compared to those with little or no USAID funding, the study found. Deaths from malaria and neglected tropical diseases were similarly cut in half. 'Time to scale up' After USAID was gutted, several other major donors including Germany, the UK and France followed suit in announcing plans to slash their foreign aid budgets. These aid reductions, particularly in the European Union, could lead to 'even more additional deaths in the coming years,' study co-author Caterina Monti of ISGlobal said. But the grim projections for deaths were based on the current amount of pledged aid, so could rapidly come down if the situation changes, the researchers emphasised. Dozens of world leaders are meeting in the Spanish city of Seville this week for the biggest aid conference in a decade. The U.S., however, will not attend. 'Now is the time to scale up, not scale back,' Rasella said. Before its funding was slashed, USAID represented 0.3 percent of all U.S. federal spending. 'U.S. citizens contribute about 17 cents per day to USAID, around $64 per year,' said study co-author James Macinko of the University of California, Los Angeles. 'I think most people would support continued USAID funding if they knew just how effective such a small contribution can be to saving millions of lives.'
Globe and Mail
3 hours ago
- Globe and Mail
Oracle (ORCL) Stock Hits an All-Time High Amid Increased Cloud Demand
Optimism surrounding Oracle's ORCL cloud and AI infrastructure endeavors pushed its stock to an all-time high of $228 a share on Monday. This comes as the enterprise cloud leader has secured lucrative contracts thanks to its momentum in AI, with many analysts starting to raise their price targets for Oracle stock. That said, let's see if now is a good time to buy ORCL for higher highs. Massive Cloud Deal & AI Momentum Although the identity of the customer was not disclosed, Oracle stock spiked +4% on Monday following news of a regulatory filing in which the company had signed a massive $30 billion annual cloud services deal. Given the scale and nature of the contract, many analysts believe the client could be a major AI player like OpenAI. To that point, Oracle and OpenAI have formed a strategic partnership, collaborating on a massive AI training hub in Texas. As part of a broader $500 billion AI infrastructure initiative, which also includes Nvidia NVDA, Oracle is the venture's core infrastructure provider. Deemed Project Stargate, Oracle will be helping to expand OpenAI's compute capacity beyond Microsoft MSFT Azure. Embarking on a multi-cloud strategy, Microsoft and OpenAI are using Oracle Cloud Infrastructure (OCI) to integrate Azure's AI cloud platform to produce enhanced training for large-language models (LLMs). With demand booming for OCI, Oracle's MultiCloud revenue is reportedly growing at over 100% in correlation with the need to support generative AI workloads such as OpenAI's ChatGPT. Reporting its fiscal fourth-quarter results earlier in the month, Oracle's Q4 sales stretched 11% year over year to $15.9 billion, pinpointing that its MultiCloud database revenue spiked 115% sequentially, driven by partnerships with Amazon's AMZN AWS and Alphabet's GOOGL Google Cloud, along with Microsoft Azure. ORCL Performance & Valuation Comparison Following today's rally, ORCL is up +30% in 2025. More impressive, Oracle stock is now sitting on +200% gains in the last three years to vastly outperform the broader indexes and its Zacks Computer-Software Market's +95%, which includes Microsoft stock at +90%. Image Source: Zacks Investment Research Furthermore, despite Oracle's blazing stock performance, at 31.3X forward earnings, ORCL still trades beneath Microsoft's 37.1X and their Zacks Computer-Software Industry average of 35.9X. Analysts Upgrade ORCL Price Target to $250 Citing strong cloud momentum, AI infrastructure growth, and a bullish outlook for Oracle's current fiscal year 2026, several financial firms have upped their price target for ORCL shares to $250, including analysts at Stifel, UBS, and Guggenheim. Bottom Line At the moment, Oracle stock currently lands a Zacks Rank #3 (Hold). However, it wouldn't be surprising if a buy rating is on the way and perhaps higher highs for ORCL, as earnings estimates for Oracle are likely to rise in correlation with the announcement of its lucrative cloud services deal. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oracle Corporation (ORCL): Free Stock Analysis Report Inc. (AMZN): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report
